From the wire: Medical materials supplier DSM has announced the signing of a license and supply agreement with spinal implant and surgical systems developer SpineVision. The announcement was made at the AAOS 2013 annual meeting, which began today in Chicago.
The agreement grants SpineVision the use of Bionate II PCU, a proprietary DSM polymer, in its new Flex+2 system. The product is adaptable to the various stages of disc degeneration from early degeneration of intervertebral discs to total disc degeneration requiring fusion procedures. This level of flexibility offers spine surgeons more options in the treatment of lumbar disc diseases and allows selective segmental stabilisation to treat disc degeneration throughout multiple stages.
The Flex+2 system uses a top-loading, top-tightening design, which accommodates both open and percutaneous approaches. DSM’s Bionate II PCU encapsulates the metal wire and provides the system with enhanced frontal and sagittal stabilisation, assuring flexion and extension, which allow for increased freedom of movement and better accommodation to the spine without loss of strength or stability.
“DSM’s polyurethane materials have a proven clinical history and have been used in several dynamic stabilisation devices and implants,” said William Fuller, Director of Business Development, DSM Biomedical.“Our Bionate II PCU provides increased flexibility and shock absorbing characteristics, replicating the natural movements of the spine. We are proud to see Bionate II PCU contributing to the performance of SpineVision’s Flex+2 system.”
SpineVision will initially launch the Flex+2 system in the European Union.